Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg)

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Clinical and Experimental Immunology

• Publication date

  1993-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1365-2249.1993.tb03407.xPMID 7685668PMCID PMC1554769
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression and control of the natural autoreactive IgG repertoire in normal human serum

  1993cited by this paper
• Downregulation of the anti-HLA alloimmune response by variable region-reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates.

  1993cited by this paper
• Treatment of lupus nephritis with CD5 PLUS, an immunoconjugate of an anti-CD5 monoclonal antibody and ricin A chain.

  1992cited by this paper
• Antigen-induced apoptotic death of Ly-1 B cells responsible for autoimmune disease in transgenic mice

  1992cited by this paper
• Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain.

  1992cited by this paper
• Manipulating the immune system with immune globulin.

  1992cited by this paper
• A transgenic model of autoimmune hemolytic anemia

  1992cited by this paper
• Natural mouse IgG reacts with self antigens including molecules involved in the immune response

  1992cited by this paper
• Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg).

  1992cited by this paper
• A V region‐connected autoreactive subfraction of normal human serum immunoglobulin G

  1992cited by this paper
• Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network.

  1992cited by this paper
• Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases

  1991cited by this paper
• Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3':5'-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production.

  1991cited by this paper
• Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'.

  1991cited by this paper
• Auto‐ and Polyreactivity of IgM from CD5+ and CD5− Cord Blood B Cells

  1991cited by this paper
• Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus.

  1990cited by this paper
• Idiotypic interactions between normal human polyspecific IgG and natural IgM antibodies

  1990cited by this paper
• The CD5 B cell.

  1989cited by this paper
• B cells expressing CD5 are increased in Sjögren's syndrome.

  1988cited by this paper
• Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies.

  1988cited by this paper
• Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells from patients with rheumatoid arthritis

  1988cited by this paper
• Genetic influence on the levels of circulating CD5 B lymphocytes.

  1987cited by this paper
• Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset.

  1987cited by this paper
• Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits

  1987cited by this paper
• Rheumatoid factor secretion from human Leu-1+ B cells.

  1987cited by this paper
• Use of intravenous immunoglobulin in chronic lymphocytic leukemia.

  1984cited by this paper
• Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura.

  1983cited by this paper
• Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

  1982cited by this paper
• Natural antibodies against tubulin, actin myoglobin, thyroglobulin, fetuin, albumin and transferrin are present in normal human sera, and monoclonal immunoglobulins from multiple myeloma and Waldenström's macroglobulinemia may express similar antibody specificities.

  1981cited by this paper
• An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemic cells. Distribution on normal and malignant lymphoid cells

  1980cited by this paper

• The application of sphingomyelin in mediating the causal role of the T-cell surface glycoprotein CD5 in Crohn’s disease: A two-step Mendelian randomization study

  2024cites this paper
• Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system

  2022cites this paper
• Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy

  2021cites this paper
• Intravenous immunoglobulin as the rescue treatment in NMOSD patients

  2021cites this paper
• A systemic review of intravenous immunoglobulin G treatment in women with recurrent implantation failures and recurrent pregnancy losses

  2021cites this paper
• Application of intravenous immunoglobulin (IVIG) to modulate inflammation in critical COVID-19 – A theoretical perspective

  2021cites this paper
• Evaluation of T cell cytokines and their role in recurrent miscarriage.

  2020cites this paper
• CHAPTER 1: Literature review

  2018cites this paper
• Role of Intravenous Immunoglobulin in Dermatologic Disorders

  2018cites this paper
• IVIg therapy increases delivery birthweight in babies born to women with elevated preconception proportion of peripheral blood (CD56+/CD3-) natural killer cells.

  2017cites this paper
• The Current Status of Heart Transplantation

  2016cites this paper
• Chapter 3 The Current Status of Heart Transplantation

  2015cites this paper
• Intravenous immunoglobulin in neurology—mode of action and clinical efficacy

  2015cites this paper
• Heart Transplantation: New Realities, Challenges and Development- Demographics and Therapeutics

  2014cites this paper
• Use of Intravenous Immunoglobulin in Critically Ill Patients

  2014cites this paper
• Use of Intravenous Immunoglobulin in Critically Ill Patients

  2014cites this paper
• Use of Intravenous immune globulin in Critically Ill Patients

  2014cites this paper
• Immunomodulatory Effects of Intravenous Immunoglobulin - Assembling a Jigsaw Puzzle

  2014cites this paper
• The anti-inflammatory properties of intravenous immunoglobulin in a murine model of allergic airway disease ; effects on the development of regulatory T-cells

  2013cites this paper
• Molecular and Cellular Pathways Involved in the Anti-inflammatory Activity of IgG

  2013cites this paper
• Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

  2013cites this paper
• Igg-Reactivity of Intravenous Immunoglobulin Preparations

  2013cites this paper
• Use of intravenous immunoglobulin in the treatment of immune-mediated demyelinating diseases of the nervous system.

  2012cites this paper
• Intravenous immune globulin in autoimmune and inflammatory diseases.

  2012cites this paper
• Mechanisms of Intravenous Immunoglobulin Action in the Treatment of Autoimmune Disorders

  2012influential citation
• Alloimmunosensitization in left ventricular assist device recipients and impact on posttransplantation outcome.

  2012cites this paper
• Mechanisms of Disease Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases

  2012cites this paper
• The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders.

  2011cites this paper
• Mechanisms of Action of Intravenous Immunoglobulin in Inflammatory Muscle Disease

  2011cites this paper
• [Indications for intra-venous immunoglobulin treatment in rheumatic diseases].

  2011cites this paper
• Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis

  2010cites this paper
• Antibody‐mediated modulation of immune responses

  2010cites this paper
• Characterization of natural autoantibodies: A case for functional significance

  2010cites this paper
• Indications et mécanismes d’action des immunoglobulines intraveineuses dans les pathologies auto-immunes et inflammatoires systémiques

  2009cites this paper
• [Indications and mechanisms of action of the intravenous immunoglobulines in the systemic autoimmune and inflammatory pathologies].

  2009cites this paper
• Identification of target antigens of self‐reactive IgG in intravenous immunoglobulin preparations

  2009cites this paper
• Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies

  2009cites this paper
• Recurrent pregnancy loss: A disease of inflammation and coagulation

  2009cites this paper
• Autoantibodies to the delta-opioid receptor function as opioid agonists and display immunomodulatory activity.

  2009cites this paper
• Anti-inflammatory actions of intravenous immunoglobulin.

  2008cites this paper
• The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?

  2008cites this paper
• Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy.

  2008cites this paper
• Targeting ischemic brain injury with intravenous immunoglobulin

  2008cites this paper
• [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders].

  2007cites this paper
• Utilisation des immunoglobulines polyclonales intraveineuses dans les pathologies auto-immunes et inflammatoires

  2007cites this paper
• Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action

  2007influential citation
• Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies.

  2007cites this paper
• Intravenous Immunoglobulins in Autoimmune and Inflammatory Diseases

  2007cites this paper
• Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis.

  2006cites this paper
• Basic principles of intravenous immunoglobulin (IVIg) treatment

  2006cites this paper
• Autoantibody-induced formation of immune complexes in normal human serum.

  2006cites this paper
• Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms.

  2006cites this paper
• Intravenous Immunoglobulin Therapy in Peripheral Neuropathy

  2006cites this paper
• Comparative Analysis of Antigen Specificities in the Monomeric and Dimeric Fractions of Intravenous Immunoglobulin

  2005cites this paper
• Clinical uses of intravenous immunoglobulin

  2005cites this paper
• Intravenous immunoglobulin in neurological disorders: a mechanistic perspective

  2005cites this paper
• The Autoreactivity of Therapeutic Intravenous Immunoglobulin (IVIg) Preparations Depends on the Fractionation Methods Used

  2005cites this paper
• Principles of transplantation immunology

  2005cites this paper
• Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin

  2005cites this paper
• Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?

  2005cites this paper
• The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.

  2004cites this paper
• [Immunomodulatory effects of intravenous immunoglobulins].

  2004cites this paper
• Anti-DNA and Antiphospholipid Antibodies in IVIG Preparations: In Vivo Study in Naive Mice

  2004cites this paper
• Effets immunomodulateurs des immunoglobulines intraveineuses

  2004cites this paper
• Immunosuppression for Cardiac Transplantation

  2004cites this paper
• Intravenous immunoglobulins for the treatment of childhood autoimmune diseases

  2003cites this paper
• Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases.

  2003cites this paper
• Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases

  2003cites this paper
• Immunobiologic consequences of assist devices.

  2003cites this paper
• J. BayryM. ThirionN. MisraN. ThorenoorS. DelignatS. Lacroix-DesmazesB. Bellon

  2003cites this paper
• Interactions between the recipient immune system and the left ventricular assist device surface: immunological and clinical implications.

  2003cites this paper
• Treatment of Autoimmune Disorders

  2003cites this paper
• Intravenous immune globulins: an update for clinicians

  2003cites this paper
• Natural recognition repertoire and the evolutionary emergence of the combinatorial immune system

  2002cites this paper
• History, biological mechanisms of action and clinical indications of intravenous immunoglobulin (IVIG) preparations

  2002cites this paper
• The Immune Functions of the Spleen

  2002cites this paper
• Superantigen-like interaction of IVIG with antibody Fab fragments cloned by phage display technology

  2002cites this paper
• Natural recognition repertoire and the evolutionary emergence of the combinatorial immune system

  2002cites this paper
• High-dose intravenous immunoglobulin G treatment of myasthenia gravis

  2002cites this paper
• Immunomodulatory action of intravenous immunoglobulin

  2002cites this paper
• Superantigen-like interaction of IVIG with antibody Fab fragments cloned by phage display technology

  2002cites this paper
• Wirkmechanismen von Immunglobulinen

  2001cites this paper
• Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

  2001cites this paper
• Intravenous immune globulin effects on serum‐soluble CD5 levels in atopic dermatitis

  2001cites this paper
• Intravenous immunoglobulin as immuno-modifying treatment

  2001cites this paper
• Do Immune Complexes Formed with Autoantibodies Have a Role in the Maintenance of Immune Homeostasis Through Interaction with FC Receptors

  2000cites this paper
• Immunobiology of left ventricular assist devices.

  2000cites this paper
• Detection of Antibodies to Gangliosides and Glycolipids in Various Intravenous Immunoglobulin (IVIg) Preparations

  2000cites this paper
• Platelet‐reactive IgG antibodies cloned by phage display and panning with IVIG from three patients with autoimmune thrombocytopenia

  1999cites this paper
• Immunomodulation of Autoimmune Disease with Normal Polyspecific Immunoglobulin G (Intravenous Immunoglobulin)

  1999cites this paper
• [Immunomodulatory effects of intravenous immunoglobulins in autoimmune diseases].

  1999cites this paper
• Structure and Function of Immunoglobulins

  1999cites this paper
• Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg).

  1999cites this paper
• Effets immunomodulateurs des immunoglobulines intraveineuses au cours des maladies auto-immunes

  1999cites this paper
• Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients.

  1999cites this paper
• Mechanisms of Action of Intravenous Immunoglobulin (IVIg) in Immune-Mediated Diseases

  1999cites this paper
• Mechanisms of action of intravenous immunoglobulin (IVIg) in autoimmune and neuromuscular diseases.

  1999cites this paper
• Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines

  1999cites this paper
• Lichenoid/Interface Cutaneous Eruptions to IVIg with the Primary Infusion May Be Related to the Re-Regulation of Anti-Idiotype Network

  1998cites this paper
• Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice.

  1998cites this paper